IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc., the developer of the first rechargeable Sacral Neuromodulation (r-SNM™) System for the treatment of urinary and fecal ...
94% of Test-Phase Responders Achieved Significant Symptom Relief with Zero Serious Device-Related Adverse Events New Data Suggests 30 Minutes of Daily iSNM Therapy Provides UUI Symptom Relief ...
This x-ray of the pelvis shows an electronic nerve-stimulating device in the right iliac fossa. The procedure is ideal in this population because it is minimally invasive and highly efficacious The ...
Competition in the sacral neuromodulation space continues to breed new options for patients with bladder and bowel dysfunction. Irvine, CA-based Axonics now has FDA approval for its recharge-free ...
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...
Axonics today announced its R20 rechargeable sacral neuromodulation (SNM) system has received CE Mark approval for use in adults with overactive bladder and/or fecal incontinence. The implant can last ...
The battery-free percutaneous sacral neuromodulation system has comparable efficacy to published rates for traditional sacral neuromodulation devices. The US Food and Drug Administration (FDA) has ...
Sidra Medicine, has performed a sacral neuromodulation implantation procedure on an eight-year-old child with spina bfida,a minimally invasive solution for children suffering from severe bladder ...
Axonics Inc. received FDA approval for its recharge-free sacral neuromodulation (SNM) implantable neurostimulator (INS) for bladder and bowel dysfunction. The F15’s primary cell requires no recharging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results